MONDAY, Nov. 1 (HealthDay News) -- The injected antibiotic
Teflaro (ceftaroline fosamil) has been approved by the U.S. Food
and Drug Administration to treat bacterial infections including
community acquired bacterial pneumonia and methicillin-resistant
Staphylococcus aureus (MRSA), the agency said in a news
MRSA, resistant to a host of common antibiotics, is typically
acquired in hospitals and other health care settings.
Teflaro is among a class of antibiotics called cephalosporins,
which treat infections by interfering with the bacterial cell
In clinical testing, the most common side effects of Teflaro
included diarrhea, nausea and rash. The drug shouldn't be used by
people with a known history of allergy or sensitivity to
cephalosporins, the FDA said.
The FDA has more about